PubMed Health⌕ Search

PubMed · 12630406

Explosive events on the Sun.

Abstract

I describe two of the most dynamic and highly energetic phenomena in the Solar System--the explosive flares that can occur when plasma is confined by magnetic fields and the large-scale ejections of material known as 'coronal mass ejections'. These explosive events are poorly understood and yet occur in a variety of contexts in the Universe, ranging from planetary magnetospheres to active galactic nuclei. Understanding why flares and coronal mass ejections occur is a major goal across a wide range of space physics and astrophysics. Although explosive events from the Sun have dramatic effects on Earth, flares in other stars, for example, can be vastly more energetic and have an even more profound effect on their environment. We are now in the unprecedented position of having access to a number of space observatories dedicated to the Sun: the Yohkoh spacecraft, the Solar and Heliospheric Observatory, the Transition Region and Coronal Explorer and the Ramaty High Energy Solar Spectroscopic Imager. These cover a wide wavelength range from white light to gamma rays with both spectroscopy and imaging, and allow huge progress to be made in understanding the processes involved in such large explosions. The high-resolution data show dramatic and complex explosions of material on all spatial scales on the Sun. They have revealed that the Sun is constantly changing everywhere on its surface--something that was never imagined before. One of the mechanisms that has been proposed to account for the large energy release is magnetic reconnection. Recent observations from space increasingly support this view. This article will discuss those observations that support this model and also those that suggest different processes. The current space missions have given us an excellent insight into the actual explosive processes in the Sun. However, they have provided us with only a tantalizing glimpse of what causes the elusive trigger. Future missions such as Solar-B (the follow-on to Yohkoh), the Solar Terrestrial Relations Observatory, the Solar Dynamics Observatory and the Solar Orbiter mission will allow us to probe the trigger in a way that was not dreamt of a decade ago, by providing stereo views, measurements from Sun-grazing orbit, and much higher spatial, temporal and spectral resolution. It is an exciting time for solar physics and everything that we learn about the Sun will improve our ability to understand other magnetic phenomena in the Universe.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Louise K Harra. 2002-12-15. Explosive events on the Sun.. https://doi.org/10.1098/rsta.2002.1057

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗